MSCL — Satellos Bioscience Balance Sheet
0.000.00%
- CA$95.20m
- CA$39.25m
- 45
- 26
- 51
- 35
Annual balance sheet for Satellos Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | R2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | Interim Report |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | fx Final | fx Final | fx Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 0.051 | 3.86 | 1.42 | 29.9 | 48.5 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.353 | 0.418 | 0.192 | 0.44 | 0.435 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 0.427 | 4.31 | 1.65 | 30.4 | 50.7 |
Net Property, Plant And Equipment | 0.002 | 0.006 | 0.006 | 0.014 | 0.004 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Total Assets | 0.429 | 9.96 | 4.57 | 33.4 | 50.7 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.02 | 1.67 | 2.09 | 2.74 | 3.58 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 1.02 | 1.67 | 2.09 | 2.74 | 3.58 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -0.589 | 8.3 | 2.49 | 30.7 | 47.2 |
Total Liabilities & Shareholders' Equity | 0.429 | 9.96 | 4.57 | 33.4 | 50.7 |
Total Common Shares Outstanding |